Zubair Khalid

Virologist/Molecular Biologist | Veterinarian | Bioinformatician

Conventional & Molecular Virology • Vaccine Development • Computational Biology

Dr. Zubair Khalid is a veterinarian and virologist specializing in conventional and molecular virology, vaccine development, and computational biology. Dedicated to advancing animal health through innovative research and multi-omics approaches.

Dr. Zubair Khalid - Veterinarian, Virologist, and Vaccine Development Researcher specializing in Computational Biology, Multi-omics, Animal Health, and Infectious Disease Research

Section: Veterinary Medicine

Equine Protozoal Myeloencephalitis (EPM) in Horses: Clinical Signs and Diagnostic Approach

Equine protozoal myeloencephalitis (EPM) is an infectious disease of the central nervous system in horses caused by the protozoan parasites Sarcocystis neurona and, less commonly, Neospora hughesi. The disease produces progressive and asymmetrical neurologic deficits that range from mild gait abnormalities to sudden recumbency. Diagnosis requires a thorough neurologic examination, exclusion of other neurologic disorders, and detection of intrathecally derived antibodies against the causative parasites. This article provides horse owners, veterinary students, veterinary technicians, and veterinary professionals with a practical framework for recognizing clinical signs, selecting appropriate diagnostic tests, and interpreting results within the context of the whole patient.

At a Glance: EPM Essentials

Feature Clinical Relevance Diagnostic Consideration
Causative agents Sarcocystis neurona is most common, Neospora hughesi also causes EPM Testing should address both agents when clinically indicated
Typical presentation Progressive, asymmetrical neurologic deficits, often with muscle atrophy Neurologic examination is the foundation of diagnosis
Risk factors Presence of opossums, prior stressful health-related events, age extremes History taking should include farm environment and recent stress events
Diagnostic approach Rule out other neurologic diseases first, then test for intrathecal antibody production Serum testing alone cannot confirm EPM, CSF testing is required
Treatment availability FDA-approved anticoccidial drugs are available Treatment decisions require veterinary oversight
Prognosis Treated horses are more likely to improve than untreated horses Early recognition and treatment improve outcomes

Understanding the Causative Agents

EPM is caused by two related protozoan parasites. Sarcocystis neurona is the most frequently identified etiologic pathogen, while Neospora hughesi accounts for a smaller proportion of cases. Both organisms are apicomplexan parasites with complex life cycles involving definitive and intermediate hosts. The opossum serves as the definitive host for Sarcocystis neurona, shedding sporocysts in feces that contaminate feed, water, and pasture. Horses become infected through ingestion of these sporocysts, after which the parasites migrate to the central nervous system.

Horses are commonly infected with these parasites, but clinical disease occurs only infrequently. The factors that determine why some infected horses develop neurologic disease while others remain asymptomatic are not well understood. Epidemiologic studies have identified risk factors for EPM development, including the presence of opossums on the property and prior stressful health-related events. The national annual incidence of EPM was 1% or less depending on the primary use of the animals, with increased disease risk associated with age (1 to 5 years and greater than 13 years), season (lowest in winter months and increasing with ambient temperature), previous stressful events, the presence of opossums, the use of nonsurface water drinking systems, and failure to restrict wildlife access to feed.

Attempts to reproduce EPM experimentally have reliably induced antibody responses in challenged horses but have not consistently produced neurologic disease. Large numbers of sporocysts are apparently necessary to achieve infection, and clinical signs and abnormal central nervous system histology are seen only inconsistently. These findings suggest that host factors, including immune status, play a significant role in disease expression. Some element of the immune response appears necessary for the development of clinical signs, and immunosuppression may be involved in disease development.

Clinical Signs and Neurologic Presentation

EPM produces multifocal central nervous system disease, meaning that clinical signs reflect damage at multiple locations within the brain, brainstem, and spinal cord. The disease ranges in severity from mild lameness to sudden recumbency, and clinical signs usually are progressive. Affected horses most commonly present with abnormalities of gait, but they may also present with signs of brain disease.

Gait Abnormalities

The most common presenting complaint in EPM-affected horses is gait abnormality. Owners and veterinarians may observe ataxia, incoordination, weakness, or lameness that does not respond to conventional lameness treatments. The gait deficits are typically asymmetric, meaning that one limb or one side of the body is more severely affected than the other. This asymmetry is an important clinical feature that helps distinguish EPM from other neurologic conditions.

Horses with EPM may show a shortened stride, stumbling, or difficulty negotiating turns. Hindlimb weakness is common, and affected horses may have difficulty backing up or may drag their toes. Some horses show a characteristic "bunny hopping" gait when trotting, reflecting pelvic limb weakness and incoordination.

Muscle Atrophy and Spinal Signs

Clinical signs that are easily referred to spinal muscle pathology include atrophy of epaxial muscles, focal swelling and palpable tenderness, as well as enlarged muscles with increased tone. Less easily recognized signs include rigidity of the spine, shortened stride, hindlimb lameness, and indicators of poor performance. Atrophy of spinal muscles can be due to severe rhabdomyolysis, immune-related myopathy, or neurogenic atrophy from nerve trauma, EPM, or equine motor neuron disease.

In EPM, muscle atrophy often reflects damage to the lower motor neurons that supply specific muscle groups. Owners may notice asymmetric muscle wasting over the topline, shoulder, or hindquarters. This atrophy can be dramatic and may progress rapidly in some cases.

Brain and Cranial Nerve Signs

When EPM affects the brainstem or cerebrum, horses may show cranial nerve deficits. These can include facial nerve paralysis, head tilt, difficulty swallowing, tongue weakness, or changes in behavior. Some horses develop seizures or become recumbent when the disease is severe. Head shaking, abnormal eye position, and difficulty eating or drinking may also be observed.

Performance Issues

Some EPM-affected horses present with vague signs of poor performance instead of obvious neurologic deficits. These horses may refuse jumps, resist collection, or show a general decline in athletic ability. Riders may report that the horse feels "unbalanced" or "behind the leg." These subtle presentations can be challenging to diagnose because the signs overlap with musculoskeletal problems, behavioral issues, and other conditions.

Risk Factors and Epidemiology

Understanding the risk factors for EPM helps veterinarians and owners make informed decisions about prevention and diagnostic testing. The presence of opossums on the property is a well-documented risk factor, as opossums are the definitive host for Sarcocystis neurona. Horses that share pasture with opossum populations or that have access to feed contaminated by opossum feces are at increased risk.

Prior stressful health-related events also increase the risk of EPM development. These events may include transport, competition, surgery, illness, or other physiologic stressors. The mechanism linking stress to disease development is not fully understood, but stress-induced immunosuppression may allow latent infections to become active or may increase susceptibility to new infections.

Age is a significant risk factor, with increased disease risk associated with age 1 to 5 years and greater than 13 years. Season also plays a role, with the lowest incidence in winter months and increasing incidence as ambient temperature rises. This seasonal pattern likely reflects increased opossum activity and sporocyst survival during warmer months.

Management factors that increase risk include the use of nonsurface water drinking systems and failure to restrict wildlife access to feed. These factors highlight the importance of biosecurity and environmental management in EPM prevention.

Diagnostic Approach: From Examination to Confirmation

The diagnosis of EPM relies on the presence of neurologic signs, ruling out other neurologic disorders, and the detection of intrathecally derived antibodies to either Sarcocystis neurona or Neospora hughesi. A systematic approach to diagnosis is essential because EPM shares clinical features with many other neurologic conditions.

Step 1: Complete Neurologic Examination

The neurologic examination is the foundation of EPM diagnosis. A thorough examination should assess mental status, cranial nerve function, gait, posture, and spinal reflexes. The veterinarian should observe the horse at rest and in motion, including walking in straight lines, circling, backing, and negotiating obstacles. Tail tone, anal tone, and perineal sensation should also be assessed.

The neurologic examination helps localize lesions within the nervous system and establishes whether the disease process is multifocal. EPM typically produces multifocal signs, although some horses may show signs referable to a single lesion. The examination also helps rule out other conditions that can mimic EPM.

Step 2: Rule Out Other Neurologic Disorders

Many conditions can produce neurologic signs similar to EPM. These include cervical vertebral stenotic myelopathy (wobblers syndrome), equine herpesvirus myeloencephalopathy, West Nile virus encephalitis, rabies, trauma, and neoplasia. The diagnostic plan should include appropriate testing to exclude these conditions based on the clinical presentation and geographic location.

Cervical vertebral stenotic myelopathy is a common differential diagnosis, particularly in young horses. Radiography and myelography may be needed to evaluate the cervical spine. Equine herpesvirus myeloencephalopathy should be considered in horses with acute onset of neurologic signs, especially in the presence of respiratory disease or abortion on the premises. West Nile virus should be considered in unvaccinated horses during mosquito season.

Step 3: Cerebrospinal Fluid Collection and Analysis

Cerebrospinal fluid (CSF) analysis is a critical component of EPM diagnosis. CSF should be collected via lumbosacral or atlanto-occipital puncture, depending on the suspected lesion location and clinician preference. The CSF sample should be evaluated for protein concentration, nucleated cell count, and cytology. While CSF abnormalities are not specific for EPM, they help rule out other conditions such as bacterial meningitis or neoplasia.

The detection of intrathecal antibody production against the parasite is the cornerstone of EPM diagnosis. Intrathecal antibody production means that antibodies are being produced within the central nervous system compartment, which strongly supports the diagnosis of active infection. This is distinguished from passive transfer of antibodies from the bloodstream into the CSF.

Step 4: Serologic Testing

Serum testing for antibodies against Sarcocystis neurona and Neospora hughesi can provide supportive information but cannot confirm EPM on its own. Many horses have been exposed to these parasites without developing disease, and serologic surveys suggest that approximately 50% of horses in the United States have been exposed to Sarcocystis neurona. A positive serum antibody test simply indicates exposure, not active neurologic disease.

The standard immunoblot test for the detection of anti-Sarcocystis neurona antibodies in CSF has provided the most useful adjunct to a detailed neurologic examination for the diagnosis of EPM. Test sensitivity and specificity were 89% in 295 horses euthanatized because of neurologic disease, of which 123 were confirmed cases of EPM. The positive predictive value was 85%.

Step 5: Interpretation and Diagnosis

The diagnosis of EPM requires integration of clinical findings, exclusion of other conditions, and laboratory results. A horse with progressive, asymmetric neurologic deficits, no evidence of other neurologic disease, and positive CSF antibody testing for Sarcocystis neurona or Neospora hughesi is considered likely to have EPM.

It is important to recognize that CSF antibody testing has limitations. Results suggest that central nervous system infection and positive CSF immunoblot findings may be transient phenomena among naturally infected horses. A negative CSF test does not completely rule out EPM, particularly in early or mild cases. Conversely, a positive CSF test in a horse with neurologic signs consistent with EPM supports the diagnosis but does not confirm it with absolute certainty.

Comparison of Diagnostic Testing Modalities

Test Modality Sample Type What It Detects Strengths Limitations
Serum antibody testing Blood Exposure to Sarcocystis neurona or Neospora hughesi Useful for ruling out exposure, widely available Cannot distinguish exposure from active disease, high seroprevalence limits specificity
CSF antibody testing (immunoblot or ELISA) Cerebrospinal fluid Intrathecal antibody production against the parasite Supports active CNS infection, good sensitivity and specificity Requires CSF collection, results may be transient, negative results do not exclude EPM
CSF analysis (protein, cell count, cytology) Cerebrospinal fluid Inflammatory changes within the CNS Helps rule out other conditions, supports inflammatory disease Nonspecific findings, may be normal in some EPM cases
Serum to CSF titer ratio Blood and cerebrospinal fluid Intrathecally derived antibodies Helps distinguish intrathecal production from passive transfer Requires paired samples, interpretation requires clinical context
PCR on CSF Cerebrospinal fluid Parasite DNA Highly specific when positive Low sensitivity, parasites may not be present in CSF even with active disease
Postmortem histopathology and immunohistochemistry Central nervous system tissue Parasite organisms and characteristic lesions Definitive diagnosis Only available postmortem, not useful for antemortem diagnosis

Diagnostic Flowchart for EPM

The following flowchart outlines a practical approach to diagnosing EPM in horses presenting with neurologic signs.

Step 1: Initial Assessment

Begin with a complete history and physical examination. Document the onset and progression of clinical signs, any recent stressful events, and the presence of opossums or wildlife on the property. Perform a thorough neurologic examination to localize lesions and characterize the severity of deficits.

Step 2: Differential Diagnosis Consideration

Consider the most likely differential diagnoses based on signalment, history, and clinical findings. Common differentials include cervical vertebral stenotic myelopathy, equine herpesvirus myeloencephalopathy, West Nile virus encephalitis, rabies, trauma, and neoplasia. Geographic location, vaccination status, and season should inform the differential list.

Step 3: Ancillary Diagnostic Testing

Based on the differential list, perform appropriate ancillary testing. This may include cervical radiography, blood work, serology for other neurologic pathogens, and imaging studies. The goal is to rule out conditions that can mimic EPM.

Step 4: CSF Collection and Testing

If EPM remains a primary differential, collect CSF for analysis and antibody testing. Submit paired serum and CSF samples for antibody testing against Sarcocystis neurona and Neospora hughesi. Calculate serum to CSF titer ratios when appropriate.

Step 5: Interpretation and Clinical Decision

Interpret all diagnostic results in the context of the neurologic examination and exclusion of other conditions. A diagnosis of EPM is supported by compatible clinical signs, exclusion of other neurologic disorders, and evidence of intrathecal antibody production. Discuss treatment options with the owner, including the expected response and potential complications.

Step 6: Treatment Trial and Monitoring

In some cases, a treatment trial may be used to support the diagnosis. Horses that improve with anticoccidial therapy are more likely to have EPM, although response to treatment is not diagnostic. Monitor the horse's neurologic status regularly during and after treatment to assess response and detect relapse.

Treatment Options and Considerations

FDA-approved anticoccidial drugs are available for the treatment of EPM. Sulfadiazine/pyrimethamine and the triazine compounds diclazuril and ponazuril are effective anticoccidial drugs that are now available as FDA-approved treatments for EPM. Recommended treatment is use of an FDA-approved anticoccidial drug formulation, with medical and supportive treatment provided based on the severity of neurologic deficits and complications.

Treatment decisions should be made by a veterinarian based on the individual case. Factors to consider include the severity of neurologic signs, the presence of complications, cost, and owner preferences. Horses that received treatment were 10 times more likely to improve, and those that improved were 50 times more likely to survive. These statistics underscore the importance of early recognition and treatment.

Supportive Care

Supportive care is an important component of EPM management. Horses with severe neurologic deficits may require assistance with eating, drinking, and standing. Recumbent horses need aggressive nursing care to prevent pressure sores, pneumonia, and other complications. Physical therapy, including passive range of motion exercises, may help maintain muscle mass and joint function.

Monitoring Response to Treatment

Horses undergoing treatment for EPM should be monitored regularly for improvement. Neurologic examinations should be repeated at intervals determined by the attending veterinarian. Some horses show rapid improvement, while others respond more slowly or incompletely. The response to antimicrobial treatment often is incomplete, and some horses may have residual neurologic deficits even after successful treatment.

Prognosis

The prognosis for EPM varies depending on the severity of clinical signs, the duration of disease before treatment, and the response to therapy. Horses that receive treatment are more likely to improve than untreated horses. However, some horses do not return to full athletic function, and relapse is possible. Owners should discuss the expected prognosis with their veterinarian based on the individual case.

Prevention and Environmental Management

Prevention of EPM focuses on reducing exposure to infective sporocysts and minimizing stress. Because opossums are the definitive host for Sarcocystis neurona, measures that reduce opossum access to horse facilities can decrease disease risk.

Feed and Water Management

Store feed in rodent-proof and opossum-proof containers. Do not allow wildlife access to feed storage areas. Use surface water sources that are less likely to be contaminated by opossum feces, as the use of nonsurface water drinking systems has been associated with increased disease risk. Clean water troughs regularly and position them away from areas where opossums are likely to defecate.

Pasture and Facility Management

Remove opossum habitat from around horse facilities. This may include clearing brush piles, sealing access to barns and sheds, and removing potential den sites. Consider the use of fencing or other deterrents to keep opossums away from horse areas. Regular manure removal can also reduce the attractiveness of the environment to wildlife.

Stress Reduction

Because prior stressful health-related events are a risk factor for EPM development, minimizing stress may help reduce disease risk. This includes providing consistent routines, avoiding unnecessary transport, and managing horses to reduce competition and social stress. When stressful events are unavoidable, close monitoring for neurologic signs may allow earlier detection and treatment.

Common Failure Patterns in EPM Diagnosis and Management

Several common errors can delay diagnosis or compromise treatment outcomes. Recognizing these patterns can help veterinarians and owners avoid them.

Failure to Perform a Complete Neurologic Examination

A cursory examination that does not include observation at multiple gaits, circling, backing, and assessment of spinal reflexes may miss subtle neurologic deficits. The neurologic examination is the most important diagnostic tool, and it should be performed systematically and completely.

Overreliance on Serum Antibody Testing

Serum antibody testing alone cannot diagnose EPM because many healthy horses have been exposed to the parasites. A positive serum test in a horse with neurologic signs may lead to a presumptive diagnosis of EPM without appropriate exclusion of other conditions. Conversely, a negative serum test does not rule out EPM, particularly in early infection.

Failure to Rule Out Other Neurologic Diseases

EPM shares clinical features with many other neurologic conditions. Failure to consider and test for these conditions can lead to misdiagnosis and inappropriate treatment. The diagnostic plan should be tailored to the individual case and should address the most likely differential diagnoses.

Delayed Treatment

Because treatment is more likely to be effective when initiated early, delays in diagnosis can compromise outcomes. Horses with progressive neurologic signs should be evaluated promptly, and diagnostic testing should proceed efficiently.

Incomplete Treatment or Inadequate Monitoring

Some horses do not complete the full course of treatment or are not monitored adequately after treatment. This can lead to incomplete resolution of clinical signs or unrecognized relapse. Owners should follow the veterinarian's treatment and monitoring recommendations closely.

Limitations of Current Diagnostic Methods

Despite advances in EPM diagnosis, significant limitations remain. The diagnosis of EPM has improved by detecting intrathecal antibody production against the parasite, but no single test is perfect.

Sensitivity and Specificity Tradeoffs

The standard immunoblot test for anti-Sarcocystis neurona antibodies in CSF has reported sensitivity and specificity of 89%, with a positive predictive value of 85%. While these figures are encouraging, they mean that approximately 11% of confirmed EPM cases will test negative and 15% of positive tests will occur in horses without EPM.

Transient Findings

Central nervous system infection and positive CSF immunoblot findings may be transient phenomena among naturally infected horses. A horse that tests negative early in the disease course may test positive later, and a horse that tests positive may revert to negative after successful treatment. This temporal variability complicates interpretation of single test results.

Emerging Pathogens

Horses can present with clinical neurologic signs consistent with EPM while testing negative for the two main causative agents, Sarcocystis neurona or Neospora hughesi, and may still be clinically responsive to anti-parasitic drug therapy. This has led to investigation of other protozoal parasites, including Toxoplasma gondii, as potential causes of neurologic disease in horses. In one study of 210 horses presenting with clinical signs compatible with EPM, 21 horses (10.0%) had a serum to CSF ratio of 64 or less for antibodies to Toxoplasma gondii, suggesting intrathecally derived antibodies. A total of 6 animals (2.9%) presented evidence of concurrent intrathecally derived antibodies for Toxoplasma gondii and at least one other apicomplexan parasite.

Postmortem Findings

Postmortem examination remains the definitive method for confirming EPM. Histopathology with immunohistochemistry identified Sarcocystis neurona presence significantly more than PCR when directly compared. Horses chronically affected with EPM had increased degenerative changes in their central nervous system compared to acutely affected horses. The potential persistence of Sarcocystis neurona after anti-protozoal treatment has been suggested, although additional studies are warranted to further elucidate the role of the parasite in disease.

Records and Measurements for EPM Cases

Maintaining accurate records is essential for managing EPM cases and monitoring response to treatment. The following records should be maintained for each affected horse.

Initial Assessment Records

Document the date of onset of clinical signs, the progression of signs over time, and any potential precipitating events. Record the results of the complete neurologic examination, including specific deficits and their severity. Photographs and video recordings can be valuable for documenting the baseline neurologic status and tracking changes over time.

Diagnostic Testing Records

Maintain copies of all laboratory results, including serum and CSF antibody testing, CSF analysis, and any ancillary diagnostic testing. Record the dates of sample collection and the specific tests performed. This information is important for interpreting results and for comparison with future testing.

Treatment Records

Document the treatment protocol, including the drug used, dose, route of administration, and duration of treatment. Record any adverse effects or complications. Note the dates of treatment initiation and completion, as well as any changes to the treatment plan.

Monitoring Records

Schedule regular neurologic examinations during and after treatment. Record the results of each examination, noting any improvement or deterioration. Use a standardized neurologic examination form to ensure consistency across examinations. Document any residual deficits at the end of treatment and at follow-up examinations.

Welfare and Safety Considerations

EPM is a serious neurologic disease that can cause significant suffering if left untreated. Horses with severe neurologic deficits may be unable to stand, eat, or drink, and may develop complications such as pneumonia, pressure sores, and colic. Prompt diagnosis and treatment are essential for both welfare and prognostic reasons.

Pain and Distress

Horses with EPM may experience pain and distress related to their neurologic deficits. Muscle atrophy, weakness, and incoordination can make normal activities difficult or impossible. Recumbent horses are at high risk of developing pressure sores and other complications. Veterinarians should assess pain and distress regularly and provide appropriate supportive care.

Euthanasia Considerations

In severe cases, euthanasia may be the most humane option. Horses that are recumbent, unable to eat or drink, or that do not respond to treatment may have a poor quality of life. Owners should discuss the prognosis and treatment goals with their veterinarian, and decisions about euthanasia should be made with the horse's welfare as the primary consideration.

Zoonotic Considerations

EPM is not considered a zoonotic disease. The parasites that cause EPM in horses do not pose a significant risk to human health. However, good hygiene practices should always be followed when handling horses and their body fluids.

Professional Escalation Criteria

Veterinarians and owners should recognize when a case requires escalation to a specialist or referral facility. The following situations warrant consideration of referral to a veterinary neurologist or equine referral center.

Severe or Rapidly Progressive Neurologic Signs

Horses with severe neurologic deficits, including recumbency, should be referred to a facility with the capacity for intensive care and advanced diagnostic imaging. Rapidly progressive signs may indicate a more aggressive disease process or a condition other than EPM.

Diagnostic Uncertainty

When the diagnosis is unclear after initial testing, referral for advanced imaging or additional diagnostic testing may be warranted. Magnetic resonance imaging of the brain and cervical spine can help rule out structural lesions and other causes of neurologic signs.

Poor Response to Treatment

Horses that do not respond to appropriate treatment within a reasonable timeframe should be re-evaluated. The diagnosis may be incorrect, or the horse may have a complication that requires additional management. Referral for a second opinion or advanced diagnostics may be appropriate.

Complications

Horses that develop complications such as pneumonia, colic, or laminitis may require intensive care that is not available in all practices. Referral to a hospital with 24-hour monitoring and treatment capabilities should be considered.

Practical Decision Framework: Staging EPM Cases by Clinical Severity and Diagnostic Confidence

A structured staging system helps veterinarians and owners make consistent management decisions when EPM is suspected. The framework below organizes cases into three stages based on clinical severity and diagnostic confidence. This approach supports timely treatment decisions while acknowledging that EPM diagnosis is not always straightforward.

Stage 1: Suspected EPM with Mild or Ambiguous Signs

Horses in this stage show subtle neurologic deficits that may be intermittent or difficult to distinguish from musculoskeletal problems. Common presentations include mild hindlimb ataxia, subtle toe dragging, reduced performance, or vague stiffness that does not respond to conventional lameness treatment. The neurologic examination may reveal mild proprioceptive deficits, but findings are not clearly multifocal or asymmetric.

For Stage 1 cases, the primary goal is systematic documentation and monitoring. Perform a complete neurologic examination and record findings using a standardized scoring system. Video recordings of the horse walking in straight lines, circling in both directions, backing, and navigating obstacles provide objective baseline data. Repeat the neurologic examination at 7 to 14 day intervals to document progression or stability.

Diagnostic testing in Stage 1 should focus on ruling out more common conditions first. Musculoskeletal evaluation, including flexion tests and diagnostic analgesia, may be warranted if lameness is a prominent feature. Basic blood work can help identify metabolic or infectious causes of weakness. Serum antibody testing for Sarcocystis neurona and Neospora hughesi can establish exposure status, but a positive result does not confirm EPM.

Cerebrospinal fluid collection may be deferred in Stage 1 if signs are very mild and other diagnoses are being pursued. However, if neurologic deficits are confirmed on repeated examinations and other conditions have been ruled out, CSF testing should be performed. The decision to pursue CSF analysis depends on the progression of signs, the value of the horse, and the owner's willingness to pursue treatment.

Stage 2: Confirmed or Highly Likely EPM with Moderate Signs

Horses in Stage 2 have clear neurologic deficits that are consistent with EPM. Clinical findings typically include asymmetric ataxia, muscle atrophy, cranial nerve deficits, or multifocal signs that localize to multiple regions of the central nervous system. Other neurologic conditions have been ruled out through appropriate testing, and CSF analysis supports the diagnosis through detection of intrathecally derived antibodies.

For Stage 2 cases, treatment should be initiated promptly. FDA-approved anticoccidial drugs include sulfadiazine/pyrimethamine, diclazuril, and ponazuril. The choice of drug depends on factors such as cost, availability, ease of administration, and veterinarian preference. Treatment duration is determined by the attending veterinarian based on clinical response and may extend beyond the initial course.

Establish a monitoring schedule before starting treatment. Neurologic examinations should be repeated at defined intervals, typically every 2 to 4 weeks during treatment. Use the same standardized examination form and video protocol to ensure consistent comparison. Document the severity of each neurologic deficit and note any new signs that develop.

Owners should be counseled about the expected timeline for improvement. Some horses show noticeable improvement within the first 2 weeks of treatment, while others respond more slowly. The response to antimicrobial treatment often is incomplete, and some horses may have residual neurologic deficits even after successful treatment. Horses that received treatment were 10 times more likely to improve, and those that improved were 50 times more likely to survive.

Stage 3: Severe EPM or Poor Response to Treatment

Horses in Stage 3 have severe neurologic deficits, including recumbency, or have failed to improve despite appropriate treatment. These cases require intensive management and careful reassessment of the diagnosis.

Recumbent horses need aggressive nursing care to prevent complications such as pressure sores, pneumonia, and colic. Assistance with eating and drinking may be necessary. Physical therapy, including passive range of motion exercises, can help maintain joint function and muscle mass. The prognosis for recumbent horses is guarded, and euthanasia may be the most humane option if the horse does not show meaningful improvement within a defined timeframe.

For horses that do not respond to treatment, reconsider the diagnosis. EPM shares clinical features with many other neurologic conditions, and the initial diagnosis may be incorrect. Advanced imaging, including magnetic resonance imaging of the brain and cervical spine, may be warranted to rule out structural lesions. Referral to a veterinary neurologist or equine referral center should be considered when diagnostic uncertainty persists.

Recent evidence suggests that Sarcocystis neurona may persist in the central nervous system after anti-protozoal treatment. Histopathology analysis revealed that horses chronically affected with EPM had increased degenerative changes in their central nervous system compared to acutely affected horses. The potential persistence of the parasite after treatment has been suggested, although additional studies are warranted to further elucidate the role of the parasite in disease.

Decision Matrix for Treatment Initiation

Clinical Scenario Diagnostic Confidence Recommended Action Monitoring Interval
Mild gait abnormality, no confirmed neurologic deficits Low Repeat neurologic examination, rule out musculoskeletal causes, consider serum testing 7 to 14 days
Mild neurologic deficits, other conditions ruled out Moderate CSF collection and antibody testing, consider treatment if CSF supports EPM 2 to 4 weeks
Moderate asymmetric ataxia, positive CSF antibody testing High Initiate FDA-approved anticoccidial treatment 2 to 4 weeks
Severe neurologic deficits or recumbency High Immediate treatment, intensive supportive care, consider referral Daily to weekly
No improvement after 4 to 6 weeks of treatment Reassess Reconsider diagnosis, advanced imaging, referral 2 to 4 weeks

Record System for EPM Case Management

A standardized record system supports consistent evaluation and documentation of EPM cases. The following components should be included in the medical record for each affected horse.

Baseline Neurologic Examination Form

Create a form that documents each component of the neurologic examination. Include sections for mental status, cranial nerve function, gait evaluation at walk and trot, circling in both directions, backing, tail tone, anal tone, and spinal reflexes. Use a numeric scoring system for each parameter, such as 0 for normal, 1 for mild deficit, 2 for moderate deficit, and 3 for severe deficit. Record the date, time, and examiner for each examination.

Video Documentation Protocol

Standardize video recordings to ensure consistent comparison over time. Record the horse walking and trotting in a straight line away from and toward the camera, circling in both directions, backing, and navigating a small obstacle. Use the same location and lighting conditions for each recording. Store videos in the horse's medical record with clear labeling of the date and examination number.

Treatment Log

Maintain a detailed treatment log that includes the drug name, dose, route of administration, frequency, and duration. Record the dates of treatment initiation and any dose adjustments. Note any adverse effects or complications, including gastrointestinal upset, diarrhea, or signs of drug intolerance. Document the date of treatment completion and any recommendations for follow-up.

Progress Notes

Write progress notes after each neurologic examination that summarize the findings, compare them to previous examinations, and document any changes in the treatment plan. Include specific observations about gait quality, muscle condition, and cranial nerve function. Note any new signs that develop and any concerns raised by the owner or handler.

Troubleshooting Common Management Challenges

Several challenges commonly arise during EPM case management. Anticipating these challenges and having a plan for addressing them improves outcomes.

Difficulty Administering Oral Medications

Some horses resist oral administration of anticoccidial drugs. Options include mixing the medication with feed, using a dose syringe, or dividing the dose to improve palatability. If oral administration is not possible, discuss alternative formulations or routes with the veterinarian.

Gastrointestinal Upset During Treatment

Anticoccidial drugs can cause gastrointestinal upset in some horses. Monitor feed intake, fecal output, and hydration status during treatment. If diarrhea or decreased appetite develops, contact the veterinarian for guidance. Do not discontinue treatment without veterinary advice.

Lack of Apparent Response to Treatment

Some horses do not show noticeable improvement within the first few weeks of treatment. This does not necessarily mean the treatment is failing. Neurologic recovery can be slow, and residual deficits may persist. Continue treatment as prescribed and maintain the monitoring schedule. If no improvement is seen after 4 to 6 weeks, the veterinarian should reassess the diagnosis and consider additional testing.

Relapse After Treatment Completion

Some horses relapse after treatment is completed. Owners should monitor for return of neurologic signs and report any concerns promptly. The veterinarian may recommend a second course of treatment or additional diagnostic testing if relapse occurs.

Integrating the Framework into Practice

The staging framework provides a practical structure for managing EPM cases from initial suspicion through treatment and monitoring. It supports consistent decision-making, thorough documentation, and clear communication with owners. The framework is not a substitute for professional veterinary judgment but rather a tool to organize clinical reasoning and ensure that important steps are not overlooked.

Veterinarians should adapt the framework to their practice setting and the individual case. Factors such as the horse's value, intended use, and owner resources will influence diagnostic and treatment decisions. The framework should be used in conjunction with the diagnostic flowchart and comparison of testing modalities presented elsewhere in this article.

Limitations of the Staging Framework

The staging framework is a clinical tool based on current understanding of EPM, but it has limitations. The boundaries between stages are not always clear, and some horses may move between stages as their condition changes. The framework does not account for all possible clinical presentations or complications. Diagnostic testing has inherent limitations, and no test can confirm EPM with absolute certainty. The framework should be applied flexibly and in consultation with a veterinarian who can interpret findings in the context of the individual horse.

Frequently Asked Questions

What causes equine protozoal myeloencephalitis?

EPM is caused by two related protozoan parasites, Sarcocystis neurona and Neospora hughesi. Sarcocystis neurona is the most common etiologic pathogen. Horses become infected by ingesting sporocysts shed in the feces of the definitive host, which is the opossum for Sarcocystis neurona. The parasites then migrate to the central nervous system, where they cause inflammation and tissue damage.

How do horses get EPM?

Horses get EPM by ingesting infective sporocysts that contaminate feed, water, or pasture. The sporocysts are shed in the feces of opossums, which are the definitive host for Sarcocystis neurona. Horses are commonly infected, but clinical disease occurs only infrequently. Risk factors for disease development include the presence of opossums, prior stressful health-related events, age extremes, and certain management practices.

What are the early signs of EPM in horses?

Early signs of EPM can be subtle and may include mild gait abnormalities, stumbling, toe dragging, or poor performance. Some horses show asymmetric muscle atrophy, particularly over the topline or hindquarters. Because these signs overlap with many other conditions, a thorough neurologic examination is essential for early detection.

How is EPM diagnosed in horses?

EPM is diagnosed through a combination of neurologic examination findings, exclusion of other neurologic disorders, and detection of intrathecally derived antibodies against Sarcocystis neurona or Neospora hughesi in cerebrospinal fluid. Serum antibody testing alone cannot confirm EPM because many healthy horses have been exposed to the parasites.

Can a horse recover from EPM?

Many horses with EPM improve with appropriate treatment. Horses that received treatment were 10 times more likely to improve, and those that improved were 50 times more likely to survive. However, the response to antimicrobial treatment often is incomplete, and some horses may have residual neurologic deficits. Early recognition and treatment improve the chances of a favorable outcome.

What is the treatment for EPM in horses?

Treatment for EPM involves the use of FDA-approved anticoccidial drugs, including sulfadiazine/pyrimethamine, diclazuril, and ponazuril. Treatment decisions should be made by a veterinarian based on the individual case. Supportive care, including assistance with eating, drinking, and standing, may be needed for horses with severe neurologic deficits.

Is EPM contagious between horses?

EPM is not directly contagious between horses. Horses become infected by ingesting sporocysts shed in the feces of the definitive host, not through contact with infected horses. However, multiple horses on the same property may be at risk if they share the same environment and are exposed to the same contaminated feed or water sources.

How can EPM be prevented?

EPM prevention focuses on reducing exposure to infective sporocysts and minimizing stress. Store feed in wildlife-proof containers, use surface water sources, remove opossum habitat from around horse facilities, and minimize stressful events. Because prior stressful health-related events are a risk factor for EPM, managing stress may help reduce disease risk.

Related Veterinary Guides

References and Further Reading

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.